Igniting Hope: AusperBio Secures $50M to Advance Hepatitis B Cure!
- AusperBio successfully closes an oversubscribed $50 million Series B+ financing round.
- Funding will accelerate the clinical development of AHB-137, a promising functional cure for Chronic Hepatitis B (CHB).
- AHB-137 has received Breakthrough Therapy Designation, underscoring its potential.
In a landmark move to combat a global health crisis, AusperBio, a pioneering biopharmaceutical company, has electrified the medical community by securing a massive $50 million in an oversubscribed Series B+ financing round7. This powerful injection of capital, following a strong $73 million Series B earlier in 2024, signals unwavering investor confidence in AusperBio's revolutionary approach to conquering Chronic Hepatitis B (CHB), a disease affecting millions worldwide.
The funds are set to supercharge the development of AusperBio's lead candidate, AHB-137, a novel antisense oligonucleotide therapy. Built on their proprietary Med-Oligo™ ASO platform, AHB-137 has already demonstrated compelling safety and efficacy in early trials, earning it a coveted Breakthrough Therapy Designation from China's NMPA3. This designation will fast-track its journey to patients.
With ongoing Phase 2 trials in China and plans for expansion outside mainland China2, 5, 7, AHB-137 is rapidly advancing. "AusperBio is committed to delivering patient-centered innovations, aiming to alleviate the global health burden of CHB and transform treatment paradigms," the company stated, underscoring their mission. This funding not only propels AHB-137 towards becoming a functional cure but also supports the expansion of commercial manufacturing and the growth of AusperBio's broader pipeline, which leverages their advanced platform to tackle various diseases1, 7. The dawn of a new era in CHB treatment may be upon us.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.